BAFF: A regulatory cytokine of B lymphocytes involved in autoimmunity and lymphoid cancer;BAFF: Una citoquina reguladora de linfocitos B implicada en autoinmunidad y cáncer linfoide

Revista Medica de Chile

Volumn 134, Issue 9, 2006, Pages 1175-1184

  Reyes S, Lilian I ^a   León B, Francisca ^a   Rozas V, M Fernanda ^a   González J, Patricia ^a   Naves P, Rodrigo ^a  

^a UNIVERSIDAD DEL DESARROLLO   (Chile)

Author keywords

Autoimmunity; B cell activating factors; Cytokines

Indexed keywords

B CELL ACTIVATING FACTOR; CYTOKINE; TUMOR NECROSIS FACTOR RECEPTOR;

ANIMAL; AUTOIMMUNE DISEASE; AUTOIMMUNITY; B LYMPHOCYTE; DISEASE MODEL; HUMAN; IMMUNOLOGY; LYMPHOMA; METABOLISM; PHYSIOLOGY; REVIEW;

ANIMALS; AUTOIMMUNE DISEASES; AUTOIMMUNITY; B-CELL ACTIVATING FACTOR; B-LYMPHOCYTES; CYTOKINES; DISEASE MODELS, ANIMAL; HUMANS; LYMPHOMA; RECEPTORS, TUMOR NECROSIS FACTOR;

EID: 33751267944     PISSN: 00349887     EISSN: 07176163     Source Type: Journal    
DOI: None     Document Type: Review

References (67)

1. Naves R, Bono MR. Citoquinas. En: Palomo I, FA, Sepúlveda C, Rosemblatt M, Vergara U. Fundamentos de Inmunología básica y clínica. Talca: Editorial Universidad de Talca, 2002; 211-37.
2. Mackay F, Woodcock SA, Lawton P, Ambrose C, Baetscher M, Schneider P et al. Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J Exp Med 1999; 190: 1697-710.
3. Moore PA, Belvedere O, Orr A, Pieri K, Lafleur DW, Feng P et al. BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator. Science 1999; 285: 260-3.
4. Schneider P, Mackay F, Steiner V, Hofmann K, Bodmer JL, Holler N et al. BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J Exp Med 1999; 189: 1747-56.
5. Allman D, Lindsley RC, Demuth W, Rudd K, Shinton S, Hardy RR. Resolution of three nonproliferative immature splenic B cell subsets reveals multiple selection points during peripheral B cell maturation. J Immunol 2001; 167: 6834-40.
6. Loder N. Tiny chromosome is rich in genes and medical promise. Nature 1999; 402: 448.
7. Batten M, Groom J, Cachero TG, Qian F, Schneider P, Tschopp J et al. BAFF mediates survival of peripheral immature B lymphocytes. J Exp Med 2000; 192: 1453-66.
8. Do RK, Hatada E, Lee H, Tourigny MR, Hilbert D, Chen-Kiang S. Attenuation of apoptosis underlies B lymphocyte stimulator enhancement of humoral immune response. J Exp Med 2000; 192: 953-64.
9. Huard B, Arlettaz L, Ambrose C, Kindler V, Mauri D, Roosnek E et al. BAFF production by antigen-presenting cells provides T cell co-stimulation. Int Immunol 2004; 16: 467-75.
10. Ng LG, Sutherland AP, Newton R, Qian F, Cachero TG, Scott ML et al. B cell-activating factor belonging to the TNF family (BAFF)-R is the principal BAFF receptor facilitating BAFF costimulation of circulating T and B cells. J Immunol 2004; 173: 807-17.
11. Schiemann B, Gommerman JL, Vora K, Cachero TG, Shulga-Morskaya S, Dobles M et al. An essential role for BAFF in the normal development of B cells through a BCMA-independent pathway. Science 2001; 293: 2111-4.
12. Mackay F, Ambrose C. The TNF family members BAFF and APRIL: the growing complexity. Cytokine Growth Factor Rev 2003; 14: 311-24.
13. Nardelli B, Belvedere O, Roschke V, Moore PA, Olsen HS, Migone TS et al. Synthesis and release of B-lymphocyte stimulator from myeloid cells. Blood 2001; 97: 198-204.
14. Scapini P, Nardelli B, Nadali G, Calzetti F, Pizzolo G, Montecucco C et al. G-CSF-stimulated neutrophils are a prominent source of functional BLyS. J Exp Med 2003; 197: 297-302.
15. Ohata J, Zvaifler NJ, Nishio M, Boyle DL, Kalled SL, Carson DA et al. Fibroblast-like synoviocytes of mesenchymal origin express functional B cell-activating factor of the TNF family in response to proinflammatory cytokines. J Immunol 2005; 174: 864-70.
16. Krumbholz M, Theil D, Derfuss T, Rosenwald A, Schrader F, Monoranu CM et al. BAFF is produced by astrocytes and up-regulated in multiple sclerosis lesions and primary central nervous system lymphoma. J Exp Med 2005; 201: 195-200.
17. Hase H, Kanno Y, Kojima M, Hasegawa K, Sakurai D, Kojima H et al. BAFF/BLyS can potentiate B-cell selection with the B-cell coreceptor complex. Blood 2004; 103: 2257-65.
18. Zhang X, Park CS, Yoon SO, Li L, Hsu YM, Ambrose C et al. BAFF supports human B cell differentiation in the lymphoid follicles through distinct receptors. Int Immunol 2005; 17: 779-88.
19. Gorelik L, Gilbride K, Dobles M, Kalled SL, Zandman Dscott ML. Normal B cell homeostasis requires B cell activation factor production by radiation-resistant cells. J Exp Med 2003; 198: 937-45.
20. Nishio M, Endo T, Tsukada N, Ohata J, Kitada S, Reed JC et al. Nurselike cells express BAFF and APRIL, which can promote survival of chronic lymphocytic leukemia cells via a paracrine pathway distinct from that of SDF-1{alpha}. Blood 2005.
21. Litinskiy MB, Nardelli B, Hilbert DM, He B, Schaffer A, Casali P et al. DCs induce CD40-independent immunoglobulin class switching through BLyS and APRIL. Nat Immunol 2002; 3: 822-9.
22. Craxton A, Magaletti D, Ryan Ejclark EA. Macrophage- and dendritic cell-dependent regulation of human B-cell proliferation requires the TNF family ligand BAFF. Blood 2003; 101: 4464-71.
23. Hanada T, Yoshida H, Kato S, Tanaka K, Masutani K, Tsukada J et al. Suppressor of cytokine signaling-1 is essential for suppressing dendritic cell activation and systemic autoimmunity. Immunity 2003; 19: 437-50.
24. Shu HB, Hu Whjohnson H. TALL-1 is a novel member of the TNF family that is downregulated by mitogens. J Leukoc Biol 1999; 65: 680-3.
25. Novak AJ, Darce JR, Arendt BK, Harder B, Henderson K, Kindsvogel W et al. Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival. Blood 2004; 103: 689-94.
26. Thompson JS, Bixler SA, Qian F, Vora K, Scott ML, Cachero TG et al. BAFF-R, a newly identified TNF receptor that specifically interacts with BAFF. Science 2001; 293: 2108-11.
27. Avery DT, Kalled SL, Ellyard JI, Ambrose C, Bixler SA, Thien M et al. BAFF selectively enhances the survival of plasmablasts generated from human memory B cells. J Clin Invest 2003; 112: 286-97.
28. Tarte K, De Vos J, Thykjaer T, Zhan F, Fiol G, Costes V et al. Generation of polyclonal plasmablasts from peripheral blood B cells: a normal counterpart of malignant plasmablasts. Blood 2002; 100: 1113-22.
29. Tarte K, Zhan F, De Vos J, Klein B, Shaughnessy J Jr. Gene expression profiling of plasma cells and plasmablasts: toward a better understanding of the late stages of B-cell differentiation. Blood 2003; 102: 592-600.
30. Yan M, Brady JR, Chan B, Lee WP, Hsu B, Harless S et al. Identification of a novel receptor for B lymphocyte stimulator that is mutated in a mouse strain with severe B cell deficiency. Curr Biol 2001; 11: 1547-52.
31. Rahman ZS, Rao SP, Kalled Slmanser T. Normal induction but attenuated progression of germinal center responses in BAFF and BAFF-R signaling-deficient mice. J Exp Med 2003; 198: 1157-69.
32. Vora KA, Wang LC, Rao SP, Liu ZY, Majeau GR, Cutler AH et al. Cutting edge: germinal centers formed in the absence of B cell-activating factor belonging to the TNF family exhibit impaired maturation and function. J Immunol 2003; 171: 547-51.
33. Yan M, Marsters SA, Grewal IS, Wang H, Ashkenazi Adixit VM. Identification of a receptor for BLyS demonstrates a crucial role in humoral immunity. Nat Immunol 2000; 1: 37-41.
34. O'Connor BP, Raman VS, Erickson LD, Cook WJ, Weaver LK, Ahonen C et al. BCMA is essential for the survival of long-lived bone marrow plasma cells. J Exp Med 2004; 199: 91-8.
35. Seshasayee D, Valdez P, Yan M, Dixit VM, Tumas D, Grewal IS. Loss of TACI causes fatal lymphoproliferation and autoimmunity, establishing TACI as an inhibitory BLyS receptor. Immunity 2003; 18: 279-88.
36. Von Bulow GU, Van Deursen Jmbram RJ. Regulation of the T-independent humoral response by TACI. Immunity 2001; 14: 573-82.
37. Yan M, Wang H, Chan B, Roose-Girma M, Erickson S, Baker T et al. Activation and accumulation of B cells in TACI-deficient mice. Nat Immunol 2001; 2: 638-43.
38. Castigli E, Wilson SA, Garibyan L, Rachid R, Bonilla F, Schneider L et al. TACI is mutant in common variable immunodeficiency and IgA deficiency. Nat Genet 2005; 37: 829-34.
39. Salzer U, Chapel HM, Webster AD, Pan-Hammarstrom Q, Schmitt-Graeff A, Schlesier M et al. Mutations in TNFRSF13B encoding TACI are associated with common variable immunodeficiency in humans. Nat Genet 2005; 37: 820-8.
40. Goldacker S, Warnatz K. Tackling the heterogeneity of CVID. Curr Opin Allergy Clin Immunol 2005; 5: 504-9.
41. Salzer U, Grimbacher B. TACItly changing tunes: farewell to a yin and yang of BAFF receptor and TACI in humoral immunity? New genetic defects in common variable immunodeficiency. Curr Opin Allergy Clin Immunol 2005; 5: 496-503.
42. Gross JA, Johnston J, Mudri S, Enselman R, Dillon SR, Madden K et al. TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature 2000; 404: 995-9.
43. Gross JA, Dillon SR, Mudri S, Johnston J, Littau A, Roque R et al. TACI-Ig neutralizes molecules critical for B cell development and autoimmune disease. impaired B cell maturation in mice lacking BLyS. Immunity 2001; 15: 289-302.
44. Cheema GS, Roschke V, Hilbert D, Stohl W. Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases. Arthritis Rheum 2001; 44: 1313-9.
45. Tan SM, Xu D, Roschke V, Perry JW, Arkfeld DG, Ehresmann GR et al. Local production of B lymphocyte stimulator protein and APRIL in arthritic joints of patients with inflammatory arthritis. Arthritis Rheum 2003; 48: 982-92.
46. Zhang J, Roschke V, Baker KP, Wang Z, Alarcon GS, Fessler BJ et al. Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus. J Immunol 2001; 166: 6-10.
47. Stohl W. SLEsystemic lupus erythematosus: a BLySful, yet BAFFling, disorder. Arthritis Res Ther 2003; 5: 136-8.
48. Groom J, Kalled SL, Cutler AH, Olson C, Woodcock SA, Schneider P et al. Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjogren's syndrome. J Clin Invest 2002; 109: 59-68.
49. Mariette X, Roux S, Zhang J, Bengoufa D, Lavie F, Zhou T et al. The level of BLyS (BAFF) correlates with the titre of autoantibodies in human Sjogren's syndrome. Ann Rheum Dis 2003; 62: 168-71.
50. Briones J, Timmerman JM, Hilbert D, Levy R. BLyS and BLyS receptor expression in non-Hodgkin's lymphoma. Exp Hematol 2002; 30: 135-41.
51. Kern C, Cornuel JF, Billard C, Tang R, Rouillard D, Stenou V et al. Involvement of BAFF and APRIL in the resistance to apoptosis of B-CLL through an autocrine pathway. Blood 2004; 103: 679-88.
52. Moreaux J, Legouffe E, Jourdan E, Quittet P, Reme T, Lugagne C et al. BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone. Blood 2004; 103: 3148-57.
53. He B, Chadburn A, Jou E, Schattner EJ, Knowles Dmcerutti A. Lymphoma B cells evade apoptosis through the TNF family members BAFF/BLyS and APRIL. J Immunol 2004; 172: 3268-79.
54. Stohl W, Cheema GS, Briggs WS, Xu D, Sosnovtseva S, Roschke V et al. B lymphocyte stimulator protein-associated increase in circulating autoantibody levels may require CD4+ T cells: lessons from HIV-infected patients. Clin Immunol 2002; 104: 115-22.
55. Rodríguez B, Valdez H, Freimuth W, Butler T, Asaad R, Lederman MM. Plasma levels of B-lymphocyte stimulator increase with HIV disease progression. Aids 2003; 17: 1983-5.
56. Moir S, Malaspina A, Pickeral OK, Donoghue ET, Vasquez J, Miller NJ et al. Decreased survival of B cells of HIV-viremic patients mediated by altered expression of receptors of the TNF superfamily. J Exp Med 2004; 200: 587-99.
57. Muro-Cacho CA, Pantaleo G, Fauci AS. Analysis of apoptosis in lymph nodes of HIV-infected persons. Intensity of apoptosis correlates with the general state of activation of the lymphoid tissue and not with stage of disease or viral burden. J Immunol 1995; 154: 5555-66.
58. Samuelsson A, Sonnerborg A, Heuts N, Coster J, Chiodi F. Progressive B cell apoptosis and expression of Fas ligand during human immunodeficiency virus type 1 infection. AIDS Res Hum Retroviruses 1997; 13: 1031-8.
59. He B, Raab-Traub N, Casali P, Cerutti A. EBV-encoded latent membrane protein 1 cooperates with BAFF/BLyS and APRIL to induce T cell-independent Ig heavy chain class switching. J Immunol 2003; 171: 5215-24.
60. Kuppers R. B cells under influence: transformation of B cells by Epstein-Barr virus. Nat Rev Immunol 2003; 3: 801-12.
61. Baker KP, Edwards BM, Main SH, Choi GH, Wager RE, Halpern WG et al. Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator. Arthritis Rheum 2003; 48: 3253-65.
62. Genovese MC. Biologic Therapies in Clinical Development for the Treatment of Rheumatoid Arthritis. J Clin Rheumatol 2005; 11: S45-54.
63. Stohl W. A therapeutic role for BLyS antagonists. Lupus 2004; 13: 317-22.
64. Frye CA, Yocum DE, Tuan R, Suyana E, Seftor EA, Seftor RE et al. An in vitro Model for Studying Mechanisms Underlying Synoviocyte-Mediated Cartilage Invasion in Rheumatoid Arthritis. Pathol Oncol Res 1996; 2: 157-166.
65. Lehmann J, Jungel A, Lehmann I, Busse F, Biskop M, Saalbach A et al. Grafting of fibroblasts isolated from the synovial membrane of rheumatoid arthritis (RA) patients induces chronic arthritis in SCID mice-A novel model for studying the arthritogenic role of RA fibroblasts in vivo. J Autoimmun 2000; 15: 301-13.
66. Neidhart M, Seemayer CA, Hummel KM, Michel BA, Gay Regay S. Functional characterization of adherent synovial fluid cells in rheumatoid arthritis: destructive potential in vitro and in vivo. Arthritis Rheum 2003; 48: 1873-80.
67. Pap T, Muller-Ladner U, Gay Regay S. Fibroblast biology. Role of synovial fibroblasts in the pathogenesis of rheumatoid arthritis. Arthritis Res 2000; 2: 361-7.